Antkiewicz-Michaluk Lucyna, Wardas Jadwiga, Michaluk Jerzy, Romaska Irena, Bojarski Andrzej, Vetulani Jerzy
Department of Biochemistry, Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland.
Int J Neuropsychopharmacol. 2004 Jun;7(2):155-63. doi: 10.1017/S1461145703004036. Epub 2004 Jan 23.
The aim of this paper was to investigate whether rotenone, a pesticide causing experimental parkinsonism, causes direct damage to dopaminergic structure when injected intracerebrally and whether this action may be prevented by peripheral administration of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), an endogenous compound with anti-dopaminergic activity. Male Wistar rats were injected unilaterally into the median forebrain bundle with 2 microg rotenone, and received 1MeTIQ, 50 mg/kg i.p. 1 h before and then daily for 21 d. To compare the effect of intracerebral and peripheral treatment, rotenone was also given once or for 7 d in a dose of 10 mg/kg s.c. Dopamine, serotonin and their metabolites were assessed by HPLC in the substantia nigra and striatum. While a single subcutaneous rotenone dose did not produce any change in striatal dopamine metabolism, the multiple treatments resulted in changes suggesting a shift in the metabolism towards oxidative desamination and reduction of O-methylation. In contrast to systemic injections, intracerebral-administered rotenone produced a decrease in dopamine and its metabolites content in the striatum (dopamine decrease by 70%) and substantia nigra (dopamine decrease by 35%), without affecting the serotonin system. As those changes were observed 21 d after the injection of rotenone, they suggest a durable neurotoxic effect. The treatment with 1MeTIQ strongly reduced the fall of striatal dopamine concentration. The data suggest that rotenone given peripherally affects metabolic processes in dopaminergic neurons, and this seems to result from its neurotoxic action, which may be observed after an intracerebral injection. 1MeTIQ is able to counteract the damaging action of rotenone and seems to be a potential neuroprotective agent.
本文旨在研究鱼藤酮(一种可导致实验性帕金森症的杀虫剂)脑内注射时是否会对多巴胺能结构造成直接损伤,以及外周给予具有抗多巴胺能活性的内源性化合物1-甲基-1,2,3,4-四氢异喹啉(1MeTIQ)是否可以预防这种作用。雄性Wistar大鼠单侧脑室内注射2微克鱼藤酮,并在注射前1小时腹腔注射50毫克/千克的1MeTIQ,之后每天注射,持续21天。为比较脑内和外周治疗的效果,还皮下注射10毫克/千克的鱼藤酮一次或连续7天。通过高效液相色谱法评估黑质和纹状体内多巴胺、5-羟色胺及其代谢产物。虽然单次皮下注射鱼藤酮未引起纹状体多巴胺代谢的任何变化,但多次给药导致代谢变化,提示代谢向氧化脱氨基转变且O-甲基化减少。与全身注射不同,脑内注射鱼藤酮使纹状体(多巴胺减少70%)和黑质(多巴胺减少35%)中的多巴胺及其代谢产物含量降低,而不影响5-羟色胺系统。由于这些变化在注射鱼藤酮21天后观察到,提示其具有持久的神经毒性作用。1MeTIQ治疗可强烈降低纹状体多巴胺浓度的下降。数据表明,外周给予鱼藤酮会影响多巴胺能神经元的代谢过程,这似乎是由其脑内注射后可观察到的神经毒性作用导致的。1MeTIQ能够抵消鱼藤酮的损伤作用,似乎是一种潜在的神经保护剂。